Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818332 | 0.83 | PLA2G2A (0.41) | MAPTTP53RXFP1SMN1; SMN2PLA2G10 | |
| SCHEMBL6129670 | 0.79 | P2RX4 (0.43) | P2RX4MAPTNTRK1TP53RXFP1 | |
| SCHEMBL817878 | 0.76 | HTR6 (0.44) | PLA2G10 | |
| SCHEMBL6129667 | 0.76 | P2RX4 (0.40) | P2RX4MAPTNTRK1TP53RXFP1 | |
| SCHEMBL6925519 | 0.73 | HTR6 (0.51) | P2RX4CYP19A1KMT2AMCL1 | |
| SCHEMBL7628888 | 0.71 | ABCG2 (0.39) | KMT2ASMN1; SMN2 | |
| SCHEMBL6920470 | 0.67 | HTR6 (0.52) | P2RX4KMT2AMCL1PLA2G10 | |
| SCHEMBL818181 | 0.67 | PLA2G2A (0.52) | PLA2G10 | |
| SCHEMBL6923676 | 0.67 | HTR1A (0.45) | P2RX4CYP19A1KMT2AMCL1MAPK1 | |
| SCHEMBL14280388 | 0.66 | P2RX4 (0.77) | P2RX4NTRK1KMT2AMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259260-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | claimed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1259260-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |